The development of innovative drug industry accelerates, Hang Seng Biotechnology ETF Guotai (520930) surges over 2% intraday, industry trends and catalysts attract attention.

The development of the innovative drug industry is accelerating. On April 7, the Hang Seng BioTech ETF Cathay (520930) surged more than 2% intraday, drawing attention to industry trends and catalysts.

招商证券 noted that China’s domestic innovative drug industry is developing in a practical and rapid way, with efforts to go global accelerating continuously: in the first 1~3 months of this year, the total value of China’s innovative drug out-licensing exceeded 60 billion yuan, nearing half of the level in 2025; as of now in 2026, 10 innovative drugs have already been approved (8 domestically developed), achieving historic breakthroughs. Recently, Hong Kong-listed pharmaceutical companies have disclosed their annual reports. The overall performance of the Pharma+Biotech segment has been delivered, and BD and overseas profit-sharing are gradually reflected in company statements, supporting the cycle of innovation for high-quality companies. In addition, important academic conferences such as AACR and ASCO are coming up in the period from April to June, and multiple innovative drug companies are set to release major data in succession; catalysts are worth期待. With adjusted pharmaceutical-sector capital flows not being crowded, it is believed that in Q2, the industry’s attention and allocation across the entire market are likely to improve.

The Hang Seng BioTech Index focuses on the “crown jewel” of innovative drugs and has three advantages: leading companies concentrated × scarce futures-like liquidity × high elasticity and high Sharpe ratio. If investors want a convenient way to participate in the core leading players in innovative drugs, they can consider the Hang Seng BioTech ETF Cathay (520933) to achieve one-click allocation.

Risk warning: The mention of individual stocks is only for industry event analysis and does not constitute any recommendation or investment advice regarding any individual stock. Index short-term gains or losses are for reference only and do not represent future performance, nor do they constitute any commitment or guarantee regarding fund performance. Views may be adjusted as market conditions change, and do not constitute investment advice or commitments. The risk/return characteristics of the funds mentioned are not identical. Investors are kindly reminded to read the fund legal documents carefully, fully understand product elements, risk levels, and the principles of profit distribution, choose products that match their own risk tolerance, and invest prudently. For fund fee rates, please refer to the legal documents.

The Daily Economic News

(Editor: Zhang Xiaobo)

     【Disclaimer】This article only represents the author’s personal views and is not related to Hexun. Hexun’s website remains neutral regarding the statements and opinion judgments in the text and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content included. Readers are advised to take this article as reference only and bear all responsibility themselves. Email: news_center@staff.hexun.com

Report